Cytokine traps: multi-component, high-affinity blockers of cytokine action (original) (raw)

• van Deventer, S.J. Anti-TNF antibody treatment of Crohn's disease. Ann. Rheum. Dis. 58 (Suppl. 1), I114–1120 (1999).
  Article CAS Google Scholar
• Richard-Miceli, C. & Dougados, M. Tumour necrosis factor-α blockers in rheumatoid arthritis: Review of the clinical experience. Biodrugs 15, 251–259 (2001).
  Article CAS Google Scholar
• Elliott, M.J. et al. Treatment of rheumatoid arthritis with chimeric monoclonal antibodies to tumor necrosis factor α. Arthritis Rheum. 36, 1681–1690 (1993).
  Article CAS Google Scholar
• Goldenberg, M.M. Etanercept, a novel drug for the treatment of patients with severe, active rheumatoid arthritis. Clin. Ther. 21, 75–87 (1999).
  Article CAS Google Scholar
• Mohler, K.M. et al. Soluble tumor necrosis factor (TNF) receptors are effective therapeutic agents in lethal endotoxemia and function simultaneously as both TNF carriers and TNF antagonists. J. Immunol. 151, 1548–1561 (1993).
  CAS PubMed Google Scholar
• Bresnihan, B. et al. Treatment of rheumatoid arthritis with recombinant human interleukin-1 receptor antagonist. Arthritis Rheum. 41, 2196–2204 (1998).
  Article CAS Google Scholar
• Cohen, S., Hurd, E. & Cush, J. Treatment of interleukin-1 receptor antagonist in combination with methotrexate in rheumatoid arthritis patients. Arthritis Rheum. 42, S273 (1999).
  Article Google Scholar
• Nuki, G., Rozman, B. & Pavelka, K. Interleukin-1 receptor antagonist continues to demonstrate clinical improvement in rheumatoid arthritis. Arthritis Rheum. 40, S224 (1997).
  Google Scholar
• Campion, G.V., Lebsack, M.E., Lookabaugh, J., Gordon, G. & Catalano, M. Dose-range and dose-frequency study of recombinant human interleukin-1 receptor antagonist in patients with rheumatoid arthritis. The IL-1Ra Arthritis Study Group. Arthritis Rheum. 39, 1092–1101 (1996).
  Article CAS Google Scholar
• Bresnihan, B. The prospect of treating rheumatoid arthritis with recombinant human interleukin-1 receptor antagonist. Biodrugs 15, 87–97 (2001).
  Article CAS Google Scholar
• Borish, L.C. et al. Interleukin-4 receptor in moderate atopic asthma. A phase I/II randomized, placebo-controlled trial. Am. J. Respir. Crit. Care Med. 160, 1816–1823 (1999).
  Article CAS Google Scholar
• Borish, L.C. et al. Efficacy of soluble IL-4 receptor for the treatment of adults with asthma. J. Allergy Clin. Immunol. 107, 963–970 (2001).
  Article CAS Google Scholar
• Bataille, R. et al. Biologic effects of anti-interleukin-6 murine monoclonal antibody in advanced multiple myeloma. Blood 86, 685–691 (1995).
  CAS PubMed Google Scholar
• Haddad, E. et al. Treatment of B-lymphoproliferative disorder with a monoclonal anti-interleukin-6 antibody in 12 patients: a multicenter phase 1-2 clinical trial. Blood 97, 1590–1597 (2001).
  Article CAS Google Scholar
• Beck, J.T. et al. Brief report: Alleviation of systemic manifestations of Castleman's disease by monoclonal anti-interleukin-6 antibody. N. Engl. J. Med. 330, 602–605 (1994).
  Article CAS Google Scholar
• Legouffe, E. et al. Human anti-mouse antibody response to the injection of murine monoclonal antibodies against IL-6. Clin. Exp. Immunol. 98, 323–329 (1994).
  Article CAS Google Scholar
• Carpenter, L.R., Yancopoulos, G.D. & Stahl, N. General mechanisms of cytokine receptor signaling. Adv. Protein Chem. 52, 109–140 (1999).
  Article Google Scholar
• Davis, S. et al. LIFR β and gp130 as heterodimerizing signal transducers of the tripartite CNTF receptor. Science 260, 1805–1808 (1993).
  Article CAS Google Scholar
• Stahl, N. & Yancopoulos, G.D. The alphas, betas, and kinases of cytokine receptor complexes. Cell 74, 587–590 (1993).
  Article CAS Google Scholar
• Taga, T. et al. Interleukin-6 triggers the association of its receptor with a possible signal transducer, gp130. Cell 58, 573–581 (1989).
  Article CAS Google Scholar
• Dinarello, C.A. Biologic basis for interleukin-1 in disease. Blood 87, 2095–2147 (1996).
  CAS PubMed Google Scholar
• van den Berg, W.B., Joosten, L.A., Helsen, M. & van de Loo, F.A. Amelioration of established murine collagen-induced arthritis with anti-IL-1 treatment. Clin. Exp. Immunol. 95, 237–243 (1994).
  Article CAS Google Scholar
• Reimers, J. Interleukin-1b induced transient diabetes mellitus in rats. Danish Med. Bull. 45, 157–180 (1998).
  CAS PubMed Google Scholar
• van den Berg, W.B. Joint inflammation and cartilage destruction may occur uncoupled. Springer Semin. Immunopathol. 20, 149–164 (1998).
  Article CAS Google Scholar
• Joosten, L.A., Helsen, M.M., van de Loo, F.A. & van den Berg, W.B. Anticytokine treatment of established type II collagen-induced arthritis in DBA/1 mice. A comparative study using anti-TNF α, anti- IL-1 α/β, and IL-1Ra. Arthritis Rheum. 39, 797–809 (1996).
  Article CAS Google Scholar
• Cieslewicz, G. et al. The late, but not early, asthmatic response is dependent on IL-5 and correlates with eosinophil infiltration. J. Clin. Invest. 104, 301–308 (1999).
  Article CAS Google Scholar
• Wills-Karp, M. Immunologic basis of antigen-induced airway hyperresponsiveness. Annu. Rev. Immunol. 17, 255–281 (1999).
  Article CAS Google Scholar
• Gundel, R. et al. IL-4 induced leucocyte trafficking in cynomolgus monkeys: correlation with expression of adhesion molecules and chemokine generation. Clin. Exp. Allergy 26, 719–729 (1996).
  Article CAS Google Scholar
• Foote, J. & Eisen, H.N. Kinetic and affinity limits on antibodies produced during immune responses. Proc. Natl. Acad. Sci. USA 92, 1254–1256 (1995).
  Article CAS Google Scholar
• Guler, H.-P. et al. A phase 1, single dose escalation study of IL-1 trap in patients with rheumatoid arthritis. Arthritis Rheum. 44, S370 (2001).
• Wills-Karp, M. et al. Interleukin-13: central mediator of allergic asthma. Science 282, 2258–2261 (1998).
  Article CAS Google Scholar
• Grunig, G. et al. Requirement for IL-13 independently of IL-4 in experimental asthma. Science 282, 2261–2263 (1998).
  Article CAS Google Scholar
• Coyle, A.J. et al. Interleukin-4 is required for the induction of lung Th2 mucosal immunity. Am. J. Respir. Cell Mol. Biol. 13, 54–59 (1995).
  Article CAS Google Scholar
• Holash, J. et al. VEGF-trap: A VEGF blocker with potent antitumor effects. Proc. Natl. Acad. Sci. USA 99, 11393–11398 (2002).
  Article CAS Google Scholar
• Kim, E.S. et al. Potent VEGF blockade causes regression of coopted vessels in a model of neuroblastoma. Proc. Natl. Acad. Sci. USA 99, 11399–11404 (2002).
  Article CAS Google Scholar
• Joosten, L.A., Helsen, M.M. & van den Berg, W.B. Accelerated onset of collagen-induced arthritis by remote inflammation. Clin. Exp. Immunol. 97, 204–211 (1994).
  Article CAS Google Scholar
• Wooley, P.H. et al. The effect of an interleukin-1 receptor antagonist protein on type II collagen-induced arthritis and antigen-induced arthritis in mice. Arthritis Rheum. 36, 1305–1314 (1993).
  Article CAS Google Scholar